Anemia of Chronic Disease
Anemia of Chronic Disease
National Organization for Rare Disorders, Inc.
It is possible that the main title of the report Anemia of Chronic Disease is not the name you expected.
Anemia of chronic disease is a condition that can be associated with many different underlying disorders including chronic illnesses such as cancer, certain infections, and autoimmune and inflammatory diseases such as rheumatoid arthritis or lupus. Anemia is characterized by low levels of circulating red blood cells or hemoglobin, the part of red blood cells that carries oxygen. Anemia of chronic disease is usually a mild or moderate condition. In mild cases, anemia may not be associated with any symptoms or may cause fatigue, paleness of the skin (pallor) and lightheadedness. The underlying mechanisms that cause anemia of chronic disease are complex and not fully understood.
Anemia of chronic disease varies in severity from one person to another. In most cases, anemia is usually mild or moderate. Affected individuals may develop a variety of symptoms such as fatigue, paleness of the skin (pallor), lightheadedness, shortness of breath, a fast heartbeat, irritability, chest pain and additional findings. These symptoms may occur in any individual who has a comparable degree of anemia. In most cases, the symptoms associated with the underlying disease usually take precedent over the mild or moderate anemia symptoms. In rare cases, anemia of chronic disease can be severe and cause more serious complications.
The exact cause of anemia of chronic disease may vary. Usually several processes are occurring concurrently. Anemia can be caused by a slight shortening of normal red blood cell survival. In addition, the production of red blood cells (erythropoiesis) or erythropoietin (a hormone that stimulates red blood cell production) may be impaired. Red blood cells carry oxygen to the body. The exact cause of anemia of chronic disease may depend upon the underlying condition. For example, cancer cells may secrete certain substances that damage or destroy immature red blood cells. In some cases, cancer cells or infectious disease may infiltrate the bone marrow, the soft spongy material found in long bones where blood cells are formed.
Researchers have also learned that individuals with anemia of chronic disease also have an imbalance in the distribution of iron in the body and as a result cannot effectively use iron to create new blood cells despite having sufficient or elevated levels of iron stored in the tissues. Iron is a critical mineral that is found in all cells of the body and is essential for the body to function and grow properly. Iron is found many types of food including red meat, poultry, eggs and vegetables. Iron levels must remain in a specific range within the body, otherwise they can cause anemia (due to low functional iron levels) or damage to affected organs (due to abnormally high iron levels in certain tissues).
Iron is needed to produce hemoglobin, the part of a red blood cell that carries oxygen. A key finding in anemia of chronic disease is increased uptake and retention of iron within certain cells, which leads to reduced amounts of functional iron that is available for the production of hemoglobin. The lack of functional iron hinders the development of hemoglobin, which, in turn, reduces the amount of oxygen delivered throughout the body (anemia).
Researchers believe that the immune system, which remains constantly active in individuals with chronic diseases, produces substances that influence the development, storage and transport of iron within the body. Cells in the immune system produce cytokines, specialized proteins that stimulate or inhibit the function of other immune system cells.
Hepcidin, a hormone produced in the liver that helps regulate the metabolism and transport of iron within the body, plays a significant role in the development of anemia of chronic disease. Researchers believe a specific cytokine known as interleukin-6 (IL-6) stimulates the production of hepcidin in most cases, although hepcidin can also be produced in response to inflammation by pathways that do not involve IL-6. Excess hepcidin causes too much iron to be trapped within cells, lowering the amount of iron available to produce hemoglobin, thereby resulting in anemia. Most researchers believe that hepcidin is a key factor influencing the development of anemia of chronic disease.
Anemia of chronic disease affects males and females in equal numbers. Individuals of any age who have a chronic, inflammatory disease can potentially develop the condition. The exact incidence of anemia of chronic disease is unknown and some researchers believe that it is underreported or often goes unrecognized. Anemia of chronic disease is believed to be the second most common cause of anemia in the United States after iron-deficiency anemia.
Iron deficiency anemia is a common condition in which individuals have insufficient levels of iron in the body and cannot produce enough red blood cells to carry oxygen through the body. Iron deficiency anemia can cause a variety of symptoms including fatigue, weakness, pale skin, shortness of breath, headaches, and lightheadedness. Additional symptoms that can occur in individuals with iron deficiency anemia include cold hands or feet, irritability, irregular heartbeats and an increased susceptibility to developing infections. Iron deficiency anemia is caused by insufficient levels of iron in the body, which can occur due to blood loss, a diet that supplies little iron, or an inability to absorb sufficient amounts of iron in the gastrointestinal tract.
The anemia seen in chronic kidney disease is usually caused by erythropoietin deficiency as a result of damage to kidney cells. However, some patients with kidney disease also have inflammation or infections, and the anemia of chronic disease may be part of their anemia.
A diagnosis of anemia of chronic disease is made based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests. Such tests can measure the levels of certain substances in the body including hemoglobin levels, the levels of iron in the serum, total iron binding capacity, overall red blood cell count, or normal or increased levels of ferritin in the blood. Ferritin is a protein that binds to iron and is used as an indicator of the body's iron stores in the blood plasma. Another test that may be performed measures transferrin saturation. Transferrin is a protein that is involved in the transport of iron from the intestines into the bloodstream. Methods to allow the reliable measurement of hepcidin in plasma have been developed but are not available or approved for use in the diagnosis of anemia of chronic disease at present.
The treatment of anemia of chronic disease is geared toward the underlying disease. If the treatment of the underlying disease is successful, anemia usually improves or resolves completely without direct treatment of its own.
Efforts to treat the anemia by correcting the iron imbalance in the body with therapies such as iron supplements or vitamins have generally proven ineffective. In fact, such efforts can have negative impact on overall health. For example, iron supplementation is controversial because certain diseases such as cancer use iron to grow and spread and certain infections use iron as nourishment. More research is necessary to understand the complex mechanisms that ultimately result in anemia of chronic disease and what role, if any, that traditional therapies for anemia and iron imbalance have in the treatment of affected individuals.
In rare cases associated with severe anemia, blood transfusions or treatment with drugs that stimulate the production of erythropoietin (a hormone that stimulates red blood cell production) may be necessary. However, in some studies, individuals taking these therapies have done worse than individuals who do not take them. More research is necessary to determine the long-term safety and effectiveness such therapies for the treatment of individuals with anemia of chronic disease.
Information on current clinical trials is posted on the Internet at <a title="Clinical Trials" href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>. All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
Email: <a title="email@example.com" href="mailto:firstname.lastname@example.org" target="_blank">email@example.com</a>
For information about clinical trials sponsored by private sources, contact:
For information about clinical trials conducted in Europe, contact:
Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011;62:347-360.
Lasocki S, Longrois D, Montravera P, Beaumont C. Hepcidin and anemia in the critically ill patient: bench to bedside. Anesthesiology 2011;114:688-694
Ganz T, Nemeth E. Iron sequestration and the anemia of inflammation. Semin Hematol 2009;46:387-393.
Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023.
The Merck Manual Home Health Handbook. Anemia of Chronic Disease. September 2013. Available at: <a href="http://www.merck.com/mmhe/sec14/ch172/ch172e.html">//www.merck.com/mmhe/sec14/ch172/ch172e.html</a> Accessed March 25, 2015.
Genetic and Rare Diseases (GARD) Information Center
- PO Box 8126
- Gaithersburg, MD 20898-8126
- Tel: (301)251-4925
- Fax: (301)251-4911
- Tel: (888)205-2311
- Website: //rarediseases.info.nih.gov/GARD/
Iron Disorders Institute
- PO Box 675
- Taylors, SC 29687
- Tel: (864)292-1175
- Fax: (864)292-1878
- Tel: (888)565-4766
- Email: firstname.lastname@example.org
- Website: //www.irondisorders.org
NIH/National Heart, Lung and Blood Institute
- P.O. Box 30105
- Bethesda, MD 20892-0105
- Tel: (301)592-8573
- Fax: (301)251-1223
- Email: email@example.com
- Website: //www.nhlbi.nih.gov/
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.
For additional information and assistance about rare disorders, please visit the National Organization for Rare Disorders web site at www.rarediseases.org
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report.
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
Last Updated: 4/28/2015
Copyright 2015 National Organization for Rare Disorders, Inc.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.